SynthesisBritish journal of cancer2011
Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis.
Synthesis in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Quantitative and Qualitative Analysis of Circulating Cell-Free DNA Can Be Used as an Adjuvant Tool for Prostate Cancer Screening: A Meta-Analysis.Disease markers · 2016Pooled it
- APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis.European journal of human genetics : EJHG · 2013Pooled it
- Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis.PloS one · 2013Pooled it
- Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.Molecular oncology · 2018Trial
- Association of DSC3 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.PloS one · 2014Trial
- Liquid biopsy in the clinical management of tumor of urinary system: current status and future developments.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Establishing Clinically Significant Prostate Cancer Diagnosis Models Based on Serum Methylation Levels of Four Genes.Annals of surgical oncology · 2026Article
- ASO Author Reflections: Advancing Noninvasive Diagnosis of Prostate Cancer: Insights from Serum DNA Methylation Biomarkers.Annals of surgical oncology · 2025Article
- Could GSTP1, PTEN and NKX3.1 gene expression be novel markers in the relationship between prostate cancer and epigenetics?BMC cancer · 2025Article
- Clinical significance of urine-based automated detection of GSTP1 methylation for the diagnosis of suspected prostate cancer patients.Translational andrology and urology · 2025Article
- Methylated Reprimo Cell-Free DNA as a Non-Invasive Biomarker for Gastric Cancer.International journal of molecular sciences · 2025Article
- Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications.Cancers · 2024Review
- Identification of a Biomarker Panel from Genome-Wide Methylation to Detect Early HPV-Associated Oropharyngeal Cancer.Cancer prevention research (Philadelphia, Pa.) · 2024Article
- Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review.Cancers · 2024Review
- Article
- Cell-free DNA in the management of prostate cancer: Current status and future prospective.Asian journal of urology · 2023Review
- Glutathione-S-TransferaseInternational journal of endocrinology · 2023Review
- One-Carbon and Polyamine Metabolism as Cancer Therapy Targets.Biomolecules · 2022Review
- Role of glutathione-S-transferase gene P1 in the diagnosis of prostate cancer in patients with 'grey level' prostate-specific antigen values.Experimental and therapeutic medicine · 2022Article
- GSTT1, an increased risk factor for prostate cancer in patients with metabolic syndrome.Journal of clinical laboratory analysis · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundProstate-specific antigen (PSA) screening has low specificity. Assessment of methylation status in body fluids may complement PSA screening if the test has high specificity.
methodThe purpose of this study was to conduct a meta-analysis of the sensitivity and specificity for prostate cancer detection of glutathione-s-transferase-π (GSTP1) methylation in body fluids (plasma, serum, whole blood, urine, ejaculate, and prostatic secretions). We conducted a comprehensive literature search on Medline (Pubmed). We included studies if they met all four of the following criteria: (1) measurement of DNA methylation in body fluids; (2) a case-control or case-only design; (3) publication in an English journal; and (4) adult subjects. Reviewers conducted data extraction independently using a standardised protocol. Twenty-two studies were finally included in this paper. Primer sequences and methylation method in each study were summarised and evaluated using meta-analyses. This paper represents a unique cross-disciplinary approach to molecular epidemiology.
resultsThe pooled specificity of GSTP1 promoter methylation measured in plasma, serum, and urine samples from negative-biopsy controls was 0.89 (95% CI, 0.80-0.95). Stratified analyses consistently showed a high specificity across different sample types and methylation methods (include both primer sequences and location). The pooled sensitivity was 0.52 (95% CI, 0.40-0.64).
conclusionsThe pooled specificity of GSTP1 promoter methylation measures in plasma, serum, and urine was excellent and much higher than the specificity of PSA. The sensitivity of GSTP1 was modest, no higher than that of PSA. These results suggest that measurement of GSTP1 promoter methylation in plasma, serum, or urine samples may complement PSA screening for prostate cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.